Plasmid Name
pHCIgG1DLE
Mutation Set
S239D / A330L / I332E
Selection Marker
Ampicillin
Promoter
CMV
Fc Engineering Overview
The human IgG1 (DLE) Fc variant features a classic triple mutation engineered to maximize structural hydrophobic packing and electrostatic complementarity at the FcγRIIIa interface. This modification drives high-potency NK cell-mediated ADCC and macrophage-mediated phagocytosis while maintaining baseline complement (CDC) activity and normal FcRn recycling.
Functional Profile
| Property | Effect |
|---|---|
| FcγRIIIa binding (V158 & F158) | Ultra-High ↑↑↑ (∼100× affinity boost) |
| FcγRIIa / FcγRIIb binding | Increased ↑↑ |
| ADCC | Potently Enhanced ↑↑↑↑ |
| ADCP | Potently Enhanced ↑↑↑ |
| CDC | WT Baseline / Neutral |
| FcRn binding & half-life | Normal / WT Baseline |
| Effector Potency | Classic High-Potency ADCC Benchmark |
Mechanism of Action
The DLE Fc variant combines three synergistic substitutions within the CH2 domain: Ser239 to Asp, Ala330 to Leu, and Ile332 to Glu:
- S239D & I332E: Introduce key electrostatic interactions with positively charged receptor residues on FcγRIIIa.
- A330L: Provides hydrophobic contact optimization at the core Fc-FcγRIIIa binding interface.
This triple combination enhances receptor binding kinetics and structural stability across both V158 and F158 allotypes of FcγRIIIa, resulting in potent NK cell activation and target cell lysis without impairing FcRn endosomal recycling or complement C1q binding.
Phenotypic Effects
- Exceptional increase in NK cell recruitment and ADCC killing efficacy (~10–100× potency boost over wild-type).
- Overcomes the low-affinity FcγRIIIa-F158 patient polymorphism barrier.
- Robust activation of macrophage-mediated phagocytosis (ADCP).
- Maintains physiological complement activation (CDC) baseline.
- Preserves standard FcRn-mediated recycling and systemic clearance kinetics.
Applications
- High-potency oncology therapeutics requiring robust NK cell-mediated target elimination.
- Cell-depleting antibody formats against low-density surface antigens.
- Reference standard / benchmark control in Fc effector engineering studies.
- Preclinical development of engineered therapeutic antibodies targeting solid and hematological tumors.
Plasmid Map & Feature Annotation
Insert Structure: VH – CH1 – hinge – CH2(S239D/A330L/I332E) – CH3(wild-type)
- VH: Variable heavy domain
- CH1: Constant heavy 1
- Hinge: Native IgG1 hinge
- CH2 (S239D/A330L/I332E): ADCC/ADCP high-potency structure triple
- CH3 (WT): Native IgG1 CH3 domain
Product Note: The DLE variant (S239D/A330L/I332E) is one of the most widely cited and benchmarked high-potency Fc variants in therapeutic antibody discovery. It delivers strong NK-cell recruitment and target cytotoxicity, serving as the immediate structural stepping stone between the double mutant DE (S239D/I332E) and the quadruple hyper-enhanced variant GASDALIE (G236A/S239D/A330L/I332E).
Fusion BioLabs ADCC/ADCP-Enhanced Family Comparison Matrix
| Variant | Mechanism | Enhancement Strength | Primary Application & Notes |
|---|---|---|---|
| human IgG1 (WT) Wild-Type |
Native baseline FcγR binding | ★★☆☆☆ | Baseline Control. Standard physiological FcγR binding and ADCC/ADCP baseline for comparative assays. |
| human IgG1 (G236A) G236A |
Lower hinge FcγRIIa selective optimization | ★★★☆☆+ | Selective ADCP Enhancer. Specifically boosts macrophage phagocytosis by maximizing the FcγRIIa/FcγRIIb activation ratio. |
| human IgG1 (DE) S239D / I332E |
CH2 domain electrostatic interface enhancement | ★★★☆☆ | Moderate ADCC/ADCP Enhancer. Core double mutation boosting FcγRIIIa and FcγRIIa engagement. |
| human IgG1 (DLE) S239D / A330L / I332E |
CH2 domain structural interface enhancement | ★★★★☆ | This Product. Strong ADCC Enhancer. Classic triple mutation optimizing NK cell-mediated lysis. |
| human IgG1 (ADE) G236A / S239D / I332E |
CH2 domain multi-residue FcγRIIIa optimization | ★★★★☆+ | High-Potency ADCC/ADCP Enhancer. Increases FcγRIIIa binding while improving the FcγRIIa/FcγRIIb binding ratio to favor activation over inhibition. |
| human IgG1 (GASDALIE) G236A / S239D / A330L / I332E |
CH2 domain hyper-enhancement (FcγRIIIa & FcγRIIa) | ★★★★★ | Ultra-Potent ADCC/ADCP Enhancer. Maximum engineered affinity variant for low antigen density targets. |
Storage & Handling
- Store plasmid at −20°C.
- Avoid repeated freeze–thaw cycles.
- Use sterile technique when handling.
- Suitable for transient or stable mammalian expression (CHO, HEK293, NS0).
References
- Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11):4005-4010.
